Fresh Tracks Therapeutics, Inc.
FRTXNASDAQHealthcare
$0.94
$-0.01(-0.53%)
Market Cap$5585045
P/E Ratio—
52W High$1.0325
52W Low$0.03
Fresh Tracks Therapeutics, Inc. (FRTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FRTX · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Mar 15, 2024EPS Actual
-$0.20
Revenue
—
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Mar 15, 2024
After Market Close
FRTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2025 | Mar 4, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Dec 18, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Sep 23, 2024 | — | — | — | — | $0.01B | — |
| ◌ Q2 FY2024 | Jun 27, 2024 | — | — | — | — | $0.01B | — |
| — Q1 FY2024 | Mar 15, 2024 | — | -$0.20 | — | — | — | — |
| — Q4 FY2023 | Nov 13, 2023 | — | $0.32 | — | $0.01B | $0.00B | +287.5% |
| — Q3 FY2023 | Aug 11, 2023 | — | -$0.39 | — | $0.00B | $0.00B | -97.4% |
| — Q2 FY2023 | May 10, 2023 | — | -$1.14 | — | $0.00B | $0.00B | -99.6% |
Q1 FY2025
Mar 4, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 18, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Sep 23, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Jun 27, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 15, 2024
EPS Actual
-$0.20
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 13, 2023
EPS Actual
$0.32
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q3 FY2023
Aug 11, 2023
EPS Actual
-$0.39
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
May 10, 2023
EPS Actual
-$1.14
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q4 FY2022 | $1.95 | $1.95 | $1.95 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2022 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2024 | Mar 15, 2024 | — | $0.91 | $0.92 | +1.29% |
| — Q4 FY2023 | Nov 13, 2023 | — | $0.93 | $0.92 | -1.34% |
| — Q3 FY2023 | Aug 11, 2023 | — | $0.61 | $0.62 | +1.21% |
| — Q2 FY2023 | May 10, 2023 | — | $0.49 | $0.52 | +4.89% |
| — Q1 FY2023 | Mar 30, 2023 | — | $0.73 | $0.70 | -4.04% |
| ▼ Q4 FY2022 | Nov 10, 2022 | -9.5% | $1.73 | $1.77 | +2.31% |
| ▲ Q3 FY2022 | Aug 11, 2022 | +99.3% | $3.66 | $3.27 | -10.66% |
| ▼ Q2 FY2022 | May 12, 2022 | -39.0% | $9.00 | $9.45 | +5.00% |
Q1 FY2024+1.29%
Report Date
Mar 15, 2024
EPS Beat/Miss
—
Price Before
$0.91
Price After
$0.92
Q4 FY2023-1.34%
Report Date
Nov 13, 2023
EPS Beat/Miss
—
Price Before
$0.93
Price After
$0.92
Q3 FY2023+1.21%
Report Date
Aug 11, 2023
EPS Beat/Miss
—
Price Before
$0.61
Price After
$0.62
Q2 FY2023+4.89%
Report Date
May 10, 2023
EPS Beat/Miss
—
Price Before
$0.49
Price After
$0.52
Q1 FY2023-4.04%
Report Date
Mar 30, 2023
EPS Beat/Miss
—
Price Before
$0.73
Price After
$0.70
Q4 FY2022+2.31%
Report Date
Nov 10, 2022
EPS Beat/Miss
-9.5%
Price Before
$1.73
Price After
$1.77
Q3 FY2022-10.66%
Report Date
Aug 11, 2022
EPS Beat/Miss
+99.3%
Price Before
$3.66
Price After
$3.27
Q2 FY2022+5.00%
Report Date
May 12, 2022
EPS Beat/Miss
-39.0%
Price Before
$9.00
Price After
$9.45
Avg Beat Reaction-10.66%
Avg Miss Reaction+3.66%
Beat Rate1 / 8 quarters
Largest Move-10.66% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FRTX ends December
Fresh Tracks Therapeutics, Inc. (FRTX) most recently reported earnings on March 15, 2024 for Q1 FY2024, posting EPS of $-0.20 (in line with the analyst consensus of —). The next FRTX earnings date is expected around September 1, 2026.
Each quarter, investors track FRTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FRTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FRTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FRTX earnings · 4 questionsFresh Tracks Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. FRTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FRTX historically reports after market close (AMC).
FRTX earnings datewhen is FRTX earningsFRTX next earnings datewhen does FRTX report earningsFRTX earnings calendar
▸ Source: FMP · Fresh Tracks Therapeutics, Inc. SEC filings · US GAAP · Fresh Tracks Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026